Activation of tumor-specific CD8+ T cells after intratumoral Ad5-TRAIL/CpG oligodeoxynucleotide combination therapy

Rebecca L. VanOosten, Thomas S. Griffith

Research output: Contribution to journalArticlepeer-review

38 Scopus citations


CD8+ T-cell activation via cross-presentation of antigens from apoptotic tumor cells is controversial. Dendritic cells capture naturally shed tumor antigens and cross-present them to CD8+ T cells; unfortunately, the frequency of activated CD8+ T cells is often too low to mount an effective response against the tumor. By increasing the amount of antigen for presentation, a larger T-cell response can be theoretically elicited. We used a recombinant adenovirus encoding full-length murine tumor necrosis factor-related apoptosis-inducing ligand (Ad5-mTRAIL) to induce tumor cell apoptosis, and when given intratumorally to mice bearing experimental renal cell carcinoma (Renca) tumors, Ad5-mTRAIL minimally prolonged survival and induced a low level of CTL activity. To enhance dendritic cell efficiency, an immunostimulatory CpG oligodeoxynucleotide (CpG ODN) was combined with Ad5-mTRAIL. This combination therapy significantly augmented in vivo antigen-specific T-cell proliferation and CTL activity, as well as prolonged survival of Renca tumor-bearing mice. Interestingly, depletion of CD4+ or CD25+ cells before therapy further enhanced survival and in vivo CTL activity. In addition, tumor-free mice depleted of CD4+ cells were also able to reject a subsequent challenge of Renca cells, but not MHC-matched RM-11 prostate tumor cells, demonstrating the existence of immunologic memory. These results collectively show that local treatment with Ad5-mTRAIL and CpG ODN can augment tumor antigen cross-presentation resulting in T-cell proliferation, enhanced CTL activity, and increased animal survival.

Original languageEnglish (US)
Pages (from-to)11980-11990
Number of pages11
JournalCancer Research
Issue number24
StatePublished - Dec 15 2007


Dive into the research topics of 'Activation of tumor-specific CD8<sup>+</sup> T cells after intratumoral Ad5-TRAIL/CpG oligodeoxynucleotide combination therapy'. Together they form a unique fingerprint.

Cite this